Clinical Trial

Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

Name: Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME) — clinical trial record (NCT06942520)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ELAAVATE

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Phase 2 open label, randomized, active controlled, dose-ranging trial in adults with Center Involved - Diabetic Macular Edema (CI - DME)

Trial Details

NCT Number	NCT06942520
Lead Sponsor	Sierra Eye Associates Collaborators: REGENXBIO Inc.
Conditions	Diabetic Macular Edema
Enrollment	18 participants
Start Date	2025-03-18
Primary Completion	2027-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-04-24